As an example, combination therapy with pembrolizumab and lenvatinib for PD-L1+, treatment-naive metastatic NSCLC did not improve mOS in a recent phase III trial of 623 patients [162]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.